CL2007002593A1 - COMPOUNDS DERIVED FROM 4-HETEROARIL-PIRIDINA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REJECTION OF TRANSPLANTED ORGANS, AUTOIMMUNE SYNDROMES AND CANCER. - Google Patents

COMPOUNDS DERIVED FROM 4-HETEROARIL-PIRIDINA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REJECTION OF TRANSPLANTED ORGANS, AUTOIMMUNE SYNDROMES AND CANCER.

Info

Publication number: CL2007002593A1
Authority: CL; Chile
Prior art keywords: piridina; heteroaril; rejection; cancer; diseases
Prior art date: 2006-09-07

Application number

CL200702593A

Other languages

Spanish (es)

Inventor

Bolli David Lehmann Bor Martin

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-07

Filing date

2007-09-06

Publication date

2008-06-13

2007-09-06 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2008-06-13 Publication of CL2007002593A1 publication Critical patent/CL2007002593A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Transplantation (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL200702593A 2006-09-07 2007-09-06 COMPOUNDS DERIVED FROM 4-HETEROARIL-PIRIDINA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REJECTION OF TRANSPLANTED ORGANS, AUTOIMMUNE SYNDROMES AND CANCER. CL2007002593A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IB2006053147		2006-09-07

Publications (1)

Publication Number	Publication Date
CL2007002593A1 true CL2007002593A1 (en)	2008-06-13

Family

ID=38983600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702593A CL2007002593A1 (en)	2006-09-07	2007-09-06	COMPOUNDS DERIVED FROM 4-HETEROARIL-PIRIDINA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REJECTION OF TRANSPLANTED ORGANS, AUTOIMMUNE SYNDROMES AND CANCER.

Country Status (26)

Country	Link
US (1)	US8580824B2 (en)
EP (1)	EP2069336B1 (en)
JP (1)	JP5253401B2 (en)
KR (1)	KR101470659B1 (en)
CN (1)	CN101511827B (en)
AR (1)	AR062683A1 (en)
AU (1)	AU2007292993B2 (en)
BR (1)	BRPI0716171B8 (en)
CA (1)	CA2661105C (en)
CL (1)	CL2007002593A1 (en)
CY (1)	CY1113727T1 (en)
DK (1)	DK2069336T3 (en)
ES (1)	ES2400533T3 (en)
HR (1)	HRP20130181T1 (en)
IL (1)	IL197393A (en)
MA (1)	MA30718B1 (en)
MX (1)	MX2009002233A (en)
MY (1)	MY149853A (en)
NO (1)	NO342156B1 (en)
NZ (1)	NZ576060A (en)
PL (1)	PL2069336T3 (en)
PT (1)	PT2069336E (en)
RU (1)	RU2447071C2 (en)
SI (1)	SI2069336T1 (en)
TW (1)	TWI392671B (en)
WO (1)	WO2008029371A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0716633A2 (en) *	2006-09-08	2013-09-24	Actelion Pharmaceuticals Ltd	pyridin-3-yl derivatives, pharmaceutical composition and use of a compound as an immunomodulatory agent
KR20090051774A (en)	2006-09-21	2009-05-22	액테리온 파마슈티칼 리미티드	Phenyl derivatives and their use as immunomodulators
BRPI0720043A2 (en) *	2006-12-15	2014-01-07	Abbott Lab	OXADIAZOL COMPOUND
JO2701B1 (en)	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Compounds
CN101627034B (en) *	2007-03-16	2013-05-15	埃科特莱茵药品有限公司	Amino-pyridine derivatives as S1P1/EDG1 receptor agonists
PL2195311T3 (en) *	2007-08-17	2011-08-31	Actelion Pharmaceuticals Ltd	Pyridine derivatives as s1p1/edg1 receptor modulators
CA2700917A1 (en) *	2007-11-01	2009-05-07	Actelion Pharmaceuticals Ltd	Novel pyrimidine derivatives
US20110046170A1 (en) *	2008-03-06	2011-02-24	Martin Bolli	Novel pyrimidine-pyridine derivatives
ES2389042T3 (en) *	2008-03-06	2012-10-22	Actelion Pharmaceuticals Ltd.	Pyridine compounds
PL2252609T3 (en) *	2008-03-07	2013-09-30	Idorsia Pharmaceuticals Ltd	Pyridin-2-yl derivatives as immunomodulating agents
CA2715317A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
SI2278960T2 (en)	2008-03-17	2020-02-28	Actelion Pharmaceuticals Ltd.	Dosing regimen for a selective sip1 receptor agonist
TWI490214B (en)	2008-05-30	2015-07-01	艾德克上野股份有限公司	Benzene or thiophene derivative and use thereof as vap-1 inhibitor
NZ590474A (en)	2008-07-23	2012-10-26	Arena Pharm Inc	SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
JP5726737B2 (en)	2008-08-27	2015-06-03	アリーナファーマシューティカルズ，インコーポレイテッド	Substituted tricyclic acid derivatives as agonists of S1P1 receptors useful in the treatment of autoimmune disorders and immune disorders
US8389509B2 (en)	2009-01-23	2013-03-05	Bristol-Myers Squibb Company	Substituted pyrazole compounds
EP2389377B1 (en)	2009-01-23	2014-07-16	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
US8354398B2 (en)	2009-01-23	2013-01-15	Bristol-Myers Squibb Company	Substituted isoxazole compounds
AR075781A1 (en) *	2009-03-03	2011-04-27	Merck Serono Sa	DERIVATIVES OF OXADIAZOL PIRIDINA AS AGONISTS OF THE S1P1 / EDG1 RECEPTOR AND A METHOD FOR THEIR PREPARATION.
KR20120022757A (en) *	2009-04-17	2012-03-12	이시하라 산교 가부시끼가이샤	Method for producing 2-halogeno-6-substituted-4-trifluoromethylpyridine
DE102009002514A1 (en) *	2009-04-21	2010-10-28	Evonik Degussa Gmbh	Process for the preparation of substituted 1,4-quinone methides
ES2441845T3 (en)	2009-07-16	2014-02-06	Actelion Pharmaceuticals Ltd.	Pyridin-4-yl derivatives as S1P1 / EDG1 agonists
US8399451B2 (en)	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
EP4148045A1 (en)	2010-01-27	2023-03-15	Arena Pharmaceuticals, Inc.	Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
WO2011109471A1 (en)	2010-03-03	2011-09-09	Arena Pharmaceuticals, Inc.	Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
ES2548683T3 (en)	2010-04-23	2015-10-20	Bristol-Myers Squibb Company	4- (5-Isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl) -mandelic acid amides as sphingosine-1-phosphate receptor agonists 1
EP2595969B1 (en)	2010-07-20	2015-04-22	Bristol-Myers Squibb Company	Substituted 3-phenyl-1,2,4-oxadiazole compounds
ES2548258T3 (en)	2010-09-24	2015-10-15	Bristol-Myers Squibb Company	Oxadiazole compounds substituted and their use as S1P1 agonists
TWI546300B (en) *	2011-01-19	2016-08-21	艾克泰聯製藥有限公司	2-methoxy-pyridin-4-yl derivative
RS60408B1 (en)	2012-08-17	2020-07-31	Actelion Pharmaceuticals Ltd	Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process
CN105189487B (en)	2013-03-15	2017-12-26	爱杜西亚药品有限公司	Pyridin-4-yl derivatives
EP4445956A3 (en)	2015-01-06	2024-12-04	Arena Pharmaceuticals, Inc.	Compound for use in treating conditions related to the s1p1 receptor
BR112017024785B1 (en)	2015-05-20	2022-05-17	Idorsia Pharmaceuticals Ltd	CRYSTALLINE FORM OF COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOLE-3-YL]-2-ETHYL- 6-METHYLPHENOXY}-PROPANE-1,2-DIOL, PHARMACEUTICAL COMPOSITION, AND USE
US10111841B2 (en)	2015-06-19	2018-10-30	University Of South Florida	Stabilization of alcohol intoxication-induced cardiovascular instability
PL3310760T3 (en)	2015-06-22	2023-03-06	Arena Pharmaceuticals, Inc.	Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
WO2017004609A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Thiadiazole modulators of s1p and methods of making and using
WO2017004608A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Oxadiazole modulators of s1p methods of making and using
WO2017004610A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Tercyclic s1p3-sparing, s1p1 receptor agonists
CN110520124A (en)	2017-02-16	2019-11-29	艾尼纳制药公司	For treating the Compounds and methods for of primary biliary cholangitis
AU2018222747A1 (en)	2017-02-16	2019-09-05	Arena Pharmaceuticals, Inc.	Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN107311994A (en) *	2017-08-14	2017-11-03	淄博职业学院	A kind of novel method for synthesizing of the receptor stimulating agent drug molecules of S1P 1
PE20201170A1 (en)	2017-11-01	2020-10-28	Bristol Myers Squibb Co	BRIDGE BICYCLE COMPOUNDS AS MODULATORS OF THE X FARNESOID RECEIVER
CN109956912B (en) *	2017-12-26	2021-10-22	中国医学科学院药物研究所	Carboxylic acid compound containing diphenyloxadiazole, its preparation method and medical use
CA3102136A1 (en)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the s1p1 receptor
EP3847158A1 (en)	2018-09-06	2021-07-14	Arena Pharmaceuticals, Inc.	Compounds useful in the treatment of autoimmune and inflammatory disorders

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3647809A (en)	1968-04-26	1972-03-07	Chinoin Gyogyszer Es Vegyeszet	Certain pyridyl-1 2 4-oxadiazole derivatives
WO1991015583A1 (en)	1990-04-05	1991-10-17	The American National Red Cross	A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
AU653957B2 (en)	1990-09-20	1994-10-20	Merrell Dow Pharmaceuticals Inc.	1-aryl-3-pyridinyl-2-propene-1-ones
DE4429465A1 (en)	1994-08-19	1996-02-22	Bayer Ag	Process for the preparation of 2-halopyridine aldehydes and new 2-halopyridine aldehydes
JP2002505868A (en)	1998-03-09	2002-02-26	スミスクライン・ビーチャム・コーポレイション	Human EDG-1c polynucleotides and polypeptides and uses thereof
DE19904389A1 (en)	1999-02-04	2000-08-10	Bayer Ag	Use of substituted isoxazolecarboxylic acids and derivatives and new substances
EP1210344B1 (en)	1999-08-19	2005-10-19	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE375340T1 (en)	2001-02-21	2007-10-15	Nps Pharma Inc	HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMA RECEPTOR ANTAGONISTS
EP1575964B1 (en)	2002-01-18	2009-11-11	Merck & Co., Inc.	N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7479504B2 (en)	2002-01-18	2009-01-20	Merck & Co., Inc.	Edg receptor agonists
US20040058894A1 (en)	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
JP2005533058A (en)	2002-06-17	2005-11-04	メルク　エンド　カムパニー　インコーポレーテッド	1-((5-Aryl-1,2,4-oxadiazol-3-yl) benzyl) azetidine-3-carboxylate and 1-((5-aryl-1,2,4) as EDG receptor agonists -Oxadiazol-3-yl) benzyl) pyrrolidine-3-carboxylate
DE10237883A1 (en) *	2002-08-19	2004-03-04	Merckle Gmbh Chem.-Pharm. Fabrik	Substituted isoxazole derivatives and their use in pharmacy
AU2003279915A1 (en)	2002-10-15	2004-05-04	Merck And Co., Inc.	Process for making azetidine-3-carboxylic acid
US20050004186A1 (en)	2002-12-20	2005-01-06	Pfizer Inc	MEK inhibiting compounds
AU2004240586A1 (en)	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2005014525A2 (en)	2003-08-12	2005-02-17	Mitsubishi Pharma Corporation	Bi-aryl compound having immunosuppressive activity
RU2390519C2 (en) *	2003-08-29	2010-05-27	Оно Фармасьютикал Ко., Лтд.	Compound capable of bonding with s1p receptor and pharmaceutical application thereof
EP1670463A2 (en)	2003-10-01	2006-06-21	Merck & Co., Inc.	3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
CA2547198A1 (en)	2003-12-17	2005-06-30	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
JP2008500991A (en)	2004-05-29	2008-01-17	７ティーエムファーマエイ／エス	CRTH2 receptor ligands for medical use
WO2006010379A1 (en)	2004-07-29	2006-02-02	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as immunosuppressive agents
CA2583681A1 (en)	2004-10-22	2006-05-04	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
CA2591399C (en)	2004-12-13	2014-05-20	Ono Pharmaceutical Co., Ltd.	Aminocarboxylic acid derivative and medicinal use thereof
ATE523195T1 (en)	2005-03-23	2011-09-15	Actelion Pharmaceuticals Ltd	NEW THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR ANTAGONISTS
MX2007011670A (en)	2005-03-23	2007-11-15	Actelion Pharmaceuticals Ltd	Hydrogenated benzo (c) thiophene derivatives as immunomodulators.
SI1863474T1 (en)	2005-03-23	2009-04-30	Actelion Pharmaceuticals Ltd	Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
NZ562468A (en)	2005-04-05	2009-10-30	Pharmacopeia Inc	Purine and imidazopyridine derivatives for immunosuppression
JPWO2006115188A1 (en)	2005-04-22	2008-12-18	第一三共株式会社	Heterocyclic compounds
JP2008539195A (en)	2005-04-26	2008-11-13	ノイロサーチアクティーゼルスカブ	Novel oxadiazole derivatives and their medical use
AU2006256968A1 (en)	2005-06-08	2006-12-14	Novartis Ag	Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands
US20070043104A1 (en)	2005-06-10	2007-02-22	Luthman Ingrid K	UII-modulating compounds and their use
KR20080024533A (en)	2005-06-24	2008-03-18	액테리온 파마슈티칼 리미티드	Novel Thiophene Derivatives
WO2007001973A1 (en)	2005-06-28	2007-01-04	Astrazeneca Ab	New use
AR057894A1 (en)	2005-11-23	2007-12-26	Actelion Pharmaceuticals Ltd	THIOPHEN DERIVATIVES
TWI404706B (en)	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	Novel thiophene derivatives
CA2635124C (en)	2006-01-24	2014-04-29	Actelion Pharmaceuticals Ltd	Novel pyridine derivatives
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
CA2641661A1 (en)	2006-02-21	2007-08-30	University Of Virginia Patent Foundation	Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
EP2021338A1 (en)	2006-05-09	2009-02-11	Pfizer Products Inc.	Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
AR061841A1 (en)	2006-09-07	2008-09-24	Actelion Pharmaceuticals Ltd	DERIVATIVES OF THIOFEN-OXADIAZOLS, AGONISTS OF THE S1P1 / EDG1 RECEPTOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS IMMUNOMODULATING AGENTS.
BRPI0716633A2 (en)	2006-09-08	2013-09-24	Actelion Pharmaceuticals Ltd	pyridin-3-yl derivatives, pharmaceutical composition and use of a compound as an immunomodulatory agent
KR20090051774A (en)	2006-09-21	2009-05-22	액테리온 파마슈티칼 리미티드	Phenyl derivatives and their use as immunomodulators
KR20090057070A (en)	2006-09-29	2009-06-03	노파르티스 아게	Oxadiazole derivatives with anti-inflammatory and immunosuppressive properties
JP2008120794A (en)	2006-10-16	2008-05-29	Daiichi Sankyo Co Ltd	Pharmaceutical composition containing a heterocyclic compound
US20080138955A1 (en) *	2006-12-12	2008-06-12	Zhiyuan Ye	Formation of epitaxial layer containing silicon
BRPI0720043A2 (en)	2006-12-15	2014-01-07	Abbott Lab	OXADIAZOL COMPOUND
WO2008091967A1 (en)	2007-01-26	2008-07-31	Smithkline Beecham Corporation	Chemical compounds
CN101627034B (en)	2007-03-16	2013-05-15	埃科特莱茵药品有限公司	Amino-pyridine derivatives as S1P1/EDG1 receptor agonists
PL2195311T3 (en)	2007-08-17	2011-08-31	Actelion Pharmaceuticals Ltd	Pyridine derivatives as s1p1/edg1 receptor modulators
CA2700917A1 (en)	2007-11-01	2009-05-07	Actelion Pharmaceuticals Ltd	Novel pyrimidine derivatives
US8148410B2 (en)	2007-12-10	2012-04-03	Actelion Pharmaceuticals Ltd.	Thiophene derivatives as agonists of S1P1/EDG1
ES2389042T3 (en)	2008-03-06	2012-10-22	Actelion Pharmaceuticals Ltd.	Pyridine compounds
US20110046170A1 (en)	2008-03-06	2011-02-24	Martin Bolli	Novel pyrimidine-pyridine derivatives
PL2252609T3 (en)	2008-03-07	2013-09-30	Idorsia Pharmaceuticals Ltd	Pyridin-2-yl derivatives as immunomodulating agents
CA2715317A1 (en)	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
EP2291080B1 (en)	2008-05-14	2015-08-19	The Scripps Research Institute	Novel modulators of sphingosine phosphate receptors
ES2441845T3 (en)	2009-07-16	2014-02-06	Actelion Pharmaceuticals Ltd.	Pyridin-4-yl derivatives as S1P1 / EDG1 agonists

2007
- 2007-09-06 AU AU2007292993A patent/AU2007292993B2/en not_active Ceased
- 2007-09-06 JP JP2009527264A patent/JP5253401B2/en not_active Expired - Fee Related
- 2007-09-06 NZ NZ576060A patent/NZ576060A/en not_active IP Right Cessation
- 2007-09-06 EP EP07826287A patent/EP2069336B1/en active Active
- 2007-09-06 KR KR1020097006862A patent/KR101470659B1/en not_active Expired - Fee Related
- 2007-09-06 CL CL200702593A patent/CL2007002593A1/en unknown
- 2007-09-06 RU RU2009112538/04A patent/RU2447071C2/en active
- 2007-09-06 AR ARP070103940A patent/AR062683A1/en active IP Right Grant
- 2007-09-06 SI SI200731169T patent/SI2069336T1/en unknown
- 2007-09-06 WO PCT/IB2007/053594 patent/WO2008029371A1/en not_active Ceased
- 2007-09-06 HR HRP20130181TT patent/HRP20130181T1/en unknown
- 2007-09-06 CN CN200780033152XA patent/CN101511827B/en not_active Expired - Fee Related
- 2007-09-06 MY MYPI20090912A patent/MY149853A/en unknown
- 2007-09-06 ES ES07826287T patent/ES2400533T3/en active Active
- 2007-09-06 PL PL07826287T patent/PL2069336T3/en unknown
- 2007-09-06 BR BRPI0716171A patent/BRPI0716171B8/en not_active IP Right Cessation
- 2007-09-06 US US12/310,801 patent/US8580824B2/en active Active
- 2007-09-06 CA CA2661105A patent/CA2661105C/en active Active
- 2007-09-06 TW TW096133280A patent/TWI392671B/en not_active IP Right Cessation
- 2007-09-06 PT PT78262870T patent/PT2069336E/en unknown
- 2007-09-06 MX MX2009002233A patent/MX2009002233A/en active IP Right Grant
- 2007-09-06 DK DK07826287.0T patent/DK2069336T3/en active
2009
- 2009-03-04 IL IL197393A patent/IL197393A/en active IP Right Grant
- 2009-03-18 MA MA31729A patent/MA30718B1/en unknown
- 2009-04-06 NO NO20091394A patent/NO342156B1/en unknown
2013
- 2013-02-27 CY CY20131100186T patent/CY1113727T1/en unknown

Also Published As

Publication number	Publication date
JP5253401B2 (en)	2013-07-31
HRP20130181T1 (en)	2013-03-31
AU2007292993A1 (en)	2008-03-13
CN101511827A (en)	2009-08-19
EP2069336B1 (en)	2012-12-26
DK2069336T3 (en)	2013-02-25
ES2400533T3 (en)	2013-04-10
KR20090050102A (en)	2009-05-19
US20100063108A1 (en)	2010-03-11
CA2661105C (en)	2015-01-06
NO20091394L (en)	2009-04-06
RU2447071C2 (en)	2012-04-10
HK1133654A1 (en)	2010-04-01
BRPI0716171A8 (en)	2017-12-26
JP2010502695A (en)	2010-01-28
BRPI0716171A2 (en)	2013-09-17
CN101511827B (en)	2012-02-01
MX2009002233A (en)	2009-03-16
PL2069336T3 (en)	2013-05-31
KR101470659B1 (en)	2014-12-08
AU2007292993B2 (en)	2013-01-24
MY149853A (en)	2013-10-31
RU2009112538A (en)	2010-10-20
BRPI0716171B8 (en)	2021-05-25
AR062683A1 (en)	2008-11-26
TW200817357A (en)	2008-04-16
US8580824B2 (en)	2013-11-12
IL197393A (en)	2013-09-30
EP2069336A1 (en)	2009-06-17
NO342156B1 (en)	2018-04-09
CA2661105A1 (en)	2008-03-13
SI2069336T1 (en)	2013-03-29
PT2069336E (en)	2013-03-07
NZ576060A (en)	2011-11-25
CY1113727T1 (en)	2016-06-22
TWI392671B (en)	2013-04-11
IL197393A0 (en)	2009-12-24
BRPI0716171B1 (en)	2021-05-11
MA30718B1 (en)	2009-09-01
WO2008029371A1 (en)	2008-03-13

Publication	Publication Date	Title
CL2007002593A1 (en)	2008-06-13	COMPOUNDS DERIVED FROM 4-HETEROARIL-PIRIDINA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS REJECTION OF TRANSPLANTED ORGANS, AUTOIMMUNE SYNDROMES AND CANCER.
CL2007003774A1 (en)	2008-04-18	COMPOUNDS DERIVED FROM QUINAZOLINA SUBSTITUTES, INHIBITORS OF QUINASA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, ATEROSCLEROSIS AND ARTHRITIS.
CL2007000161A1 (en)	2008-05-30	COMPOUNDS DERIVED FROM SUBSTITUTED 2,4-DIOXOIMIDAZOLIDINE, INHIBITORS OF KINE PROTEINS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER.
CL2008001076A1 (en)	2008-10-24	COMPOUNDS DERIVED FROM SULFONAMIDE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007000806A1 (en)	2008-05-30	COMPOUNDS DERIVED FROM REPLACED HETEROPENTACICLOS; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2008001304A1 (en)	2008-09-22	COMPOUNDS DERIVED FROM REPLACED INDOL, INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP); PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS COPD, CARDIOVASCULAR DISEASE AND INFLAMMATION.
CL2008001994A1 (en)	2008-09-22	COMPOUNDS DERIVED FROM PIRAZIN-2-ONA; PHARMACEUTICAL COMBINATION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, ATEROSCLEROSIS, HYPERTENSION, AMONG OTHERS.
CL2008001025A1 (en)	2008-10-17	COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] PIRIMIDINA-2,4,6,8-TETRAONA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS METABOLIC DISORDER, DYSLIPIDEMIA AND CANCER.
CL2007002708A1 (en)	2008-04-04	COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRIDINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, CAQUEXY, INFLAMMATORY DISORDERS, AMONG OTHERS.
CL2007003879A1 (en)	2008-07-04	COMPOUNDS DERIVED FROM ARIL-CARBOXAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS ALZHEIMER, EPILEPSY AND PARKINSON.
CL2008000875A1 (en)	2008-10-03	COMPOUNDS DERIVED FROM IMIDAZOLIDIN-2-ONA; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PROFILAXIS OF DISEASES SUCH AS DYSLIPIDEMIA, DIABETES, INFLAMMATORY DISEASES, AMONG OTHERS.
CL2008000670A1 (en)	2008-11-03	Compounds derived from thiazolidinediones and substituted oxazolidinediones; pharmaceutical composition; process of preparation of the pharmaceutical composition; and use in the treatment of diseases such as rheumatoid arthritis, epoc, cancer, among others.
CL2008000690A1 (en)	2008-09-12	COMPOUNDS DERIVED FROM INDOL-3-PROPIONIC ACID; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA, HYPERTENSION; AMONG OTHER.
CL2007002513A1 (en)	2008-04-04	COMPOUNDS DERIVED FROM SUBSTITUTED ISOINDOLIN, INTERMEDIATE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND PREVENTION OF DISEASES SUCH AS CANCER, PAIN, MACULAR DEGENERATION, AMONG OTHERS.
CL2007002642A1 (en)	2008-07-18	COMPOUNDS DERIVED FROM 3- (6-OXO-1,6-DIHIDRO-PIRIDIN-3-IL) -BENZAMIDA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2007002207A1 (en)	2008-02-01	COMPOUNDS DERIVED FROM SULFONYLAMINES; PHARMACEUTICAL COMPOSITION; AND USE OF COMPOUNDS IN THE TREATMENT OF GLAUCOMA.
CL2008000434A1 (en)	2008-08-22	COMPOUNDS DERIVED FROM 2-AMINO-OXAZOLINAS; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DEPRESSION, ANXIETY, STRESS, BIPOLAR DISORDER, AMONG OTHERS.
CL2007002866A1 (en)	2008-07-04	COMPOUNDS DERIVED FROM 6-SUBSTITUTES-2- (BENCIMIDAZOLIL) PURINA AND PURINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASE, DISEASE MEDIATED BY M
CL2013001654A1 (en)	2014-03-28	Compounds derived from 6-amino-2-phenylamino-1h-benzimidazol-5-carboxamide; pharmaceutical composition; and its use in the treatment and / or prevention of inflammatory diseases and / or associated conditions, in particular pain.
CL2009000200A1 (en)	2010-09-10	Compounds derived from 2,7-naphthyridines-1-one, mediators of syk; pharmaceutical composition; and use in the treatment of inflammatory, respiratory, cellular proliferative or autoimmune disease.
CL2007002610A1 (en)	2008-02-01	COMPOUNDS DERIVED FROM REPLACED BIPIRIDINE; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PROFILAXIS OF DISEASES SUCH AS HYPERTONIA, DIABETES, MYOCARDIAL INFARTS, BETWEEN OTHERS.
CL2011000119A1 (en)	2011-06-17	Compounds derived from triazolo [4,3-a] pyridine; preparation procedure; pharmaceutical composition; and use in the treatment of diseases such as cancer.
CL2008000307A1 (en)	2008-05-30	COMPOUNDS DERIVED FROM CHROMEN-2-ONA REPLACED; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS ATEROSCLEROSIS, ASTHMA, ALLERGIC RHINITIS AND COPD.
CL2007003765A1 (en)	2008-08-22	COMPOUNDS DERIVED FROM 2-OXO-4-HIDROXI-BENZOTIAZOL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION; AND USE IN THE TREATMENT OF DISEASES SUCH AS COPD, BRONCHITIS, ASTHMA AND BRONCHIECTASIES.
CL2008000531A1 (en)	2008-09-22	COMPOUNDS DERIVED FROM HETEROCICLES, INHIBITORS OF ASPARTILPROTEASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF CARDIOVASCULAR, COGNITIVE AND NEURODEGENERATIVE DISEASES SUCH AS THE DISEASE